Author: admin

Schizophrenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approvals, Therapies, and Companies by DelveInsight

“Schizophrenia Drugs Market”
Schizophrenia companies in the market include Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, among others.

(Albany, USA) DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Schizophrenia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Schizophrenia market size from 2020 to 2034, segmented by seven major markets. The Schizophrenia Market Report also covers current Schizophrenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Schizophrenia market.

 

To Know in detail about the Schizophrenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Schizophrenia Market Forecast

 

Some of the key facts of the Schizophrenia Market Report:

  • The Schizophrenia market size was valued ~USD 7,972 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval for COBENFY™ (xanomeline and trospium chloride), an oral treatment for adult schizophrenia. COBENFY marks the first new class of medication in decades, offering a novel approach by specifically targeting M1 and M4 receptors in the brain, without blocking D2 receptors.

  • In May 2024, Teva and Medincell reported positive results from the Phase III SOLARIS trial, which evaluated the efficacy of TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injectable for adults with schizophrenia. SOLARIS is a multinational, multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of olanzapine extended-release injectable suspension for subcutaneous use in patients aged 18-65 with schizophrenia.

  • In March 2024, US-based biopharmaceutical company Acadia Pharmaceuticals announced that its Phase III ADVANCE-2 clinical trial evaluating pimavanserin for treating negative symptoms of schizophrenia failed to meet its primary endpoint. The 26-week, placebo-controlled trial enrolled 454 adult participants with negative symptoms of schizophrenia who had stable control of positive symptoms through ongoing antipsychotic therapy.

  • The US holds the largest market share for schizophrenia, valued at approximately USD 5,749 million, compared to the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

  • In 2022, Germany had the largest schizophrenia market size among the EU4 and the UK, at approximately USD 432 million. This market is expected to grow further, with Germany projected to maintain the largest share, followed by the UK, by 2034.

  • In 2022, Japan’s schizophrenia market was valued at approximately USD 676 million, making it the second largest market. This is expected to grow further by 2034.

  • According to DelveInsight’s analysis, the total diagnosed prevalent cases of schizophrenia in the 7MM were approximately 3,796,850 in 2022, and this number is expected to rise throughout the study period (2020–2034).

  • DelveInsight’s analysis estimates that in 2022, the EU4 and the UK accounted for the largest share, approximately 42%, of the total diagnosed prevalent schizophrenia cases in the 7MM. These cases are expected to increase further by 2034.

  • DelveInsight analysts reported that in 2022, the gender-specific diagnosed prevalent cases of schizophrenia in the US were approximately 757,469 for males and 655,002 for females. These numbers are expected to fluctuate throughout the forecast period (2024-2034).

  • Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others

  • Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others

  • The Schizophrenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics.

 

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Schizophrenia symptoms typically include hallucinations, delusions, disorganized thinking, and impaired cognitive function. Schizophrenia often emerges in late adolescence or early adulthood and can significantly impact daily life and social interactions.

Schizophrenia diagnosis is based on clinical assessments, psychiatric evaluations, and symptom duration. Schizophrenia treatment usually involves a combination of antipsychotic medications, psychotherapy, and social support. Schizophrenia medications, such as second-generation antipsychotics, help manage symptoms but may have side effects.

Schizophrenia causes are not fully understood, but genetic, environmental, and neurochemical factors contribute to its development. Schizophrenia research focuses on understanding brain function, improving treatments, and identifying early intervention strategies. Schizophrenia patients often require long-term care, as the condition can be episodic or continuous.

Schizophrenia burden extends beyond individuals, affecting caregivers and healthcare systems. Schizophrenia awareness and early intervention programs play a crucial role in improving outcomes. Schizophrenia-related stigma remains a challenge, making education and advocacy essential. Schizophrenia management continues to evolve with advancements in neuroscience and personalized medicine, offering hope for better therapeutic approaches in the future.

 

Get a Free sample for the Schizophrenia Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/schizophrenia-market

 

Schizophrenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Schizophrenia Epidemiology Segmentation:

The Schizophrenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Schizophrenia

  • Prevalent Cases of Schizophrenia by severity

  • Gender-specific Prevalence of Schizophrenia

  • Diagnosed Cases of Episodic and Chronic Schizophrenia

 

Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Epidemiology Forecast

 

Schizophrenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched during the study period. The analysis covers Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Schizophrenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Schizophrenia Therapies and Key Companies

  • RP5063 (brilaroxazine): Reviva Pharmaceuticals

  • MIN-101 (roluperidone): Minerva Neurosciences

  • KarXT (xanomeline-trospium): Karuna Therapeutics

  • NUPLAZID (pimavanserin): Acadia Pharmaceuticals

  • ICELPERTIN (BI-425809): Boehringer Ingelheim

  • SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical

  • OKEDI (risperidone ISM): Laboratorios Farmacéuticos Rovi

  • LYN-005: Lyndra Therapeutics

  • NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals

  • CVL-231 (emraclidine): Cerevel Therapeutics

  • Seroquel Sustained Release: AstraZeneca

  • Intramuscular Olanzapine Depot: Eli Lilly and Company

  • Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics

  • NBI-1117568: Neurocrine Biosciences

 

Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape

 

Schizophrenia Market Drivers

Increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market.

 

Schizophrenia Market Barriers

WHO’s Comprehensive Mental Health Action Plan 2013- 2030 will further enhance the awareness about mental health by ensuring 100 million more people have access to quality and affordable care for mental health conditions.

 

Scope of the Schizophrenia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmacéuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others

  • Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others

  • Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies

  • Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Schizophrenia Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

 

To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Schizophrenia Market Report Introduction

2. Executive Summary for Schizophrenia

3. SWOT analysis of Schizophrenia

4. Schizophrenia Patient Share (%) Overview at a Glance

5. Schizophrenia Market Overview at a Glance

6. Schizophrenia Disease Background and Overview

7. Schizophrenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Schizophrenia

9. Schizophrenia Current Treatment and Medical Practices

10. Schizophrenia Unmet Needs

11. Schizophrenia Emerging Therapies

12. Schizophrenia Market Outlook

13. Country-Wise Schizophrenia Market Analysis (2020–2034)

14. Schizophrenia Market Access and Reimbursement of Therapies

15. Schizophrenia Market Drivers

16. Schizophrenia Market Barriers

17. Schizophrenia Appendix

18. Schizophrenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Schizophrenia Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, Incidence, NDA Approvals, Therapies, and Companies by DelveInsight

Advanced Recurrent Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Advanced Recurrent Ovarian Cancer Pipeline Insight” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the Advanced Recurrent Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Recurrent Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Advanced Recurrent Ovarian Cancer Pipeline Report to explore emerging therapies, key Advanced Recurrent Ovarian Cancer Companies, and future Advanced Recurrent Ovarian Cancer treatment landscapes @ Advanced Recurrent Ovarian Cancer Pipeline Outlook Report

 

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

  • In February 2025:- Mayo Clinic– This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States.
  • DelveInsight’s Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
  • The leading Advanced Recurrent Ovarian Cancer Companies such as IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.
  • Promising Advanced Recurrent Ovarian Cancer Therapies such as OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin, and others.

 

Discover how the Advanced Recurrent Ovarian Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Advanced Recurrent Ovarian Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Recurrent Ovarian Cancer Clinical Trials and Studies

 

Advanced Recurrent Ovarian Cancer Emerging Drugs

 

  • Maveropepimut S: IMV

Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S’ ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients’ quality of life.

 

  • ELU 001: Elucida Oncology

ELU001 is a novel, first-in-class, new molecular entity described as a C’Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C’Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001’s high avidity is believed to promote internalization into FRα overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

 

  • A166: Klus Pharma

A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

 

The Advanced Recurrent Ovarian Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Recurrent Ovarian Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Recurrent Ovarian Cancer Treatment.
  • Advanced Recurrent Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Advanced Recurrent Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Recurrent Ovarian Cancer market.

 

Get a detailed analysis of the latest innovations in the Advanced Recurrent Ovarian Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Advanced Recurrent Ovarian Cancer Unmet Needs

 

Advanced Recurrent Ovarian Cancer Companies

IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.

 

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Download DelveInsight’s latest report to gain strategic insights into upcoming Advanced Recurrent Ovarian Cancer Therapies and key Advanced Recurrent Ovarian Cancer Developments @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

  • Coverage- Global
  • Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH and others.
  • Advanced Recurrent Ovarian Cancer Therapies- OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin, and others.
  • Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Which companies are leading the race in Advanced Recurrent Ovarian Cancer drug development? Find out in DelveInsight’s exclusive Advanced Recurrent Ovarian Cancer Pipeline Report—access it now! @ Advanced Recurrent Ovarian Cancer Emerging Drugs and Major Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Recurrent Ovarian Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Recurrent Ovarian Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Maveropepimut S: IMV
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Recurrent Ovarian Cancer Key Companies
  21. Advanced Recurrent Ovarian Cancer Key Products
  22. Advanced Recurrent Ovarian Cancer- Unmet Needs
  23. Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
  24. Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
  25. Advanced Recurrent Ovarian Cancer Analyst Views
  26. Advanced Recurrent Ovarian Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Recurrent Ovarian Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Cornmi NeoVista X7 Is Now Live on Indiegogo

We are thrilled to announce the launch of the CORNMI NeoVista X7 Lite, now live on Indiegogo! This groundbreaking device is set to redefine your visual experience with its stunning 62° FOV, 45 PPD, and 1080P high-definition display, ultra-lightweight design, and sleek, modern aesthetics. Whether you’re a tech enthusiast, a gamer, or someone who appreciates premium design, the NeoVista X7 Lite is here to impress.

Visit our Indiegogo page now to learn more and secure your device at an exclusive early-bird price:https://igg.me/at/cornmi-x7lite/x/38364133

Unmatched Visual Clarity

The NeoVista X7 Lite delivers 1080P high-definition visuals with a 62° field of view (FOV) and 45 pixels per degree (PPD), ensuring every detail is crisp and vibrant. With its advanced display technology, you’ll feel fully immersed in your favorite games, movies, or virtual experiences. The stunning clarity and vibrant colors make it a must-have for anyone seeking a superior visual experience.

Designed for Comfort and Style

Weighing in at an incredibly light weight of just 228g, the NeoVista X7 Lite is crafted for all-day comfort. Its ergonomic design and balanced weight distribution ensure that you can enjoy extended use without discomfort. Plus, its sleek, modern design makes it a stylish addition to any setup, perfect for those who value both form and function.

Early-Bird Special: Save 36%!

For a limited time, we’re offering an exclusive 36% discount for early backers on Indiegogo. This is your chance to be one of the first to experience the NeoVista X7 Lite at an unbeatable price. Don’t miss this incredible opportunity to upgrade your tech collection.

Visit our Indiegogo page now https://igg.me/at/cornmi-x7lite/x/38364133

Why Wait? Join the Revolution Today!

The CORNMI NeoVista X7 Lite is more than just a device—it’s a gateway to a new dimension of visual excellence. With its groundbreaking technology, elegant design, and unbeatable early-bird pricing, there’s never been a better time to elevate your viewing experience.

Media Contact
Company Name: CORNMI INTERNATIONAL
Contact Person: Media Manager
Email: Send Email
Country: United States
Website: https://igg.me/at/cornmi-x7lite/x/38364133

PeterTilerNSW Celebrating 18 Years of Excellence in Tiling Services in Sydney

PeterTilerNSW, a leading tiler in Sydney, is proud to announce its 18 years of commitment to transforming homes and commercial spaces across Sydney and its surrounding areas. With a focus on quality craftsmanship, customer satisfaction, and innovative design, PeterTilerNSW has continued to maintain and set new standards in the tiling industry.

Peter, the founder of PeterTilerNSW, is a seasoned tiler with many years of expertise. He believes that every space deserves to be functional and beautiful. Due to their continued effort of providing high-quality tiling services at affordable prices, they have earned and been trusted by the locals for over the years. Their services enhance aesthetics and can stand the test of time

In the quest to meet the unique needs of each customer, PeterTilerNSW offers a wide range of tiling services which include; commercial tiling, pool tiling, outdoor tiling, tile repair and restoration, bathroom renovations, kitchen renovations, and other related services with free consultation.

At PeterTilerNSW, quality work is always their top priority. They make use of the latest techniques and use the finest materials to provide the best standards for every project. Peter and his team diligently work to make sure that every tile is laid perfectly to ensure a flawless finish product to their clients.

PeterTilerNSW, the premier tiler in Sydney understands the importance of customer satisfaction, which is why their team works closely with clients throughout the entire process, from initial consultation to project completion, ensuring that every expectation is met.

They do not limit their services to Sydney alone but are dedicated to offering the best to surrounding areas, by making high-quality tiling available to a broader audience. If you have a small residential or large commercial project, the company is ready to bring vision into reality

About PeterTilerNSW

PeterTilerNSW provides high-quality tiling and relevant services in Sydney and surrounding areas in New South Wales, AU. The company was founded by Peter and his father back in 2007 as a small, local tiling company. The company later grew into a 10-man team, comprising of licensed and professional tilers who are well-trained to carry out any tasks in the residential and commercial sectors. For more information, visit their website or call them at +61408166532.

Media Contact
Company Name: PeterTilerNSW
Contact Person: Peter
Email: Send Email
Phone: +61408166532
Address:301 Crown St
City: Surry Hills
State: NSW 2010
Country: Australia
Website: https://petertilernsw.com.au/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PeterTilerNSW Celebrating 18 Years of Excellence in Tiling Services in Sydney

Dream Ellison Donates Oral Health Care Packages to Celebrate National Children’s Dental Health Month

“DeCarol Jovanovic stops by Fox 5 DC.”
After multiple appearances on Fox 5 DC, the Executive Director for Dream Ellison stopped by the studio to discuss dental health tips for children. To celebrate National Children’s Dental Health Month, children’s oral health packages were donated to the local community. During the month of February, Dream Ellison is also celebrating National Random Acts of Kindness Day by sponsoring Kindergarten families at Orange Hunt Elementary School in Springfield, VA.

DeCarol Jovanovic, Executive Director of Dream Ellison, stopped by Fox 5 DC this month to discuss dental health tips for children and bring awareness to National Children’s Dental Health Month (NCDHM). NCDHM occurs every February. Ms. Jovanovic is an oral health advocate. The Good Day DC news segment can be viewed at https://www.fox5dc.com/video/1589069.

While discussing dental tips, Ms. Jovanovic discussed brushing twice a day and preparing children for their first dental visit. In honor of NCDHM, Dream Ellison donated oral health packages to the Fort Belvoir Army Community Service for nearly 40 families. Oral health package recipients will receive a combination of children’s book about the first visit to the dentist, Kids’ toothpaste, and childrens’ toothbrushes. These packages were made possible in part due to the partnership between Dream Ellison, Eartha’s United Learning Advocacy Program, and Carrie Frasier (PaperPie Brand Partner).

During the week of February 17, 2025, Dream Ellison will celebrate National Random Acts of Kindness Day by sponsoring t-shirts for the current Kindergarten class of Orange Hunt Elementary School (OHES) located in Springfield, Virginia. Kindergarten families are able to order free t-shirts and the youngest members of the OHES student body can show their school spirit during the school year. Dream Ellison is also Silver Sponsor for the 2024-2025 School Year with the Orange Hunt Parent Teacher Association.

Dream Ellison’s next community outreach will occur as co-host of a baby shower for 40 military moms and dads on March 1, 2025 at Fort Belvoir, VA. Dream Ellison has donated diapers, wipes, and other postpartum essentials to support young military families. As a certified newborn care specialist, educational information and insights will be provided to new Moms and Dads who attend.

Media Contact
Company Name: Dream Ellison LLC
Contact Person: DeCarol Jovanovic
Email: Send Email
Country: United States
Website: https://denightshift.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dream Ellison Donates Oral Health Care Packages to Celebrate National Children’s Dental Health Month

The Experts at Granite Countertops Unlimited Discuss the Benefits of Granite for Homeowners in the Greater Cashiers NC Area

“Granite countertops can give your kitchen or bathroom an updated look with minimal upkeep. Granite Countertops Unlimited’s showroom in Cashiers NC can help you choose the right style for your space.”
While there are various solid surface countertops available, granite countertops remain a top option for homeowners aiming to enhance their kitchen or bathroom with both style and functionality. Known for their durability and high-end appearance, granite countertops provide both aesthetic appeal and practical advantages.

Granite is a popular material for countertops, offering numerous benefits to homeowners. Here are some reasons why granite is a preferred choice:

  • Unmatched Durability: Granite countertops are resistant to heat, scratches, and stains, making them ideal for high-traffic areas like kitchens and bathrooms.

  • Timeless Elegance: With unique color variations and natural patterns, granite adds sophistication and charm to any space.

  • Variety of Colors and Patterns: Granite comes in a range of hues, from bold and dramatic to subtle and understated, allowing homeowners to find the perfect match for their design style.

  • Low Maintenance: Granite is easy to clean and maintain, requiring only periodic sealing to preserve its surface.

  • Increased Home Value: Installing granite countertops can boost a home’s value, making it more appealing to prospective buyers.

Granite Countertops Unlimited: Cashiers’ Trusted Source for Affordable Granite

For homeowners in Cashiers, NC, and surrounding areas, Granite Countertops Unlimited is quickly becoming the area’s trusted provider of high-quality granite countertops. The company is well-regarded for offering both affordable options and expert installation, ensuring each project meets the highest standards.

Granite Countertops Unlimited offers:

  • Wide Selection of Granite Colors and Patterns: From sleek, modern designs to more rustic looks, Granite Countertops Unlimited provides a variety of granite options to suit every taste, from classic to trendy.

  • Expert Installation Services: Using cutting-edge technology, the team at Granite Countertops Unlimited ensures precise measurements and careful installation for a perfect fit.

  • Affordable Pricing: By importing materials directly, Granite Countertops Unlimited offers competitive pricing, ensuring homeowners can enjoy the benefits of granite without exceeding their budget.

  • Excellent Customer Service: With years of industry experience, the family-owned and operated company prides itself on offering exceptional customer service from initial consultation to final approval..

Find Granite Countertops Near Cashiers

Homeowners in Cashiers, NC, and surrounding areas searching for granite countertops near me can rely on Granite Countertops Unlimited for high-quality countertops at an affordable price. To explore the full range of granite and other stone surface options and schedule an in-person consultation at their Cashiers showroom, visit https://www.granitecountertopsunlimited.com/cashiers/. Granite Countertops Unlimited serves Cashiers, Highlands, and Glenville, NC, and the surrounding areas of Sapphire, Lake Toxaway, Franklin, and Otto, NC; Dillard, GA and Sky Valley, GA; and Upstate South Carolina, including Clemson and Greenville, SC.

About Granite Countertops Unlimited:

Granite Countertops Unlimited is a leading supplier and installer of granite countertops. The company is known for its broad selection of top-quality granite and other stone surface countertops, expert installation services, and unwavering dedication to customer satisfaction. Whether upgrading a kitchen or bathroom, Granite Countertops Unlimited offers professional service and competitive pricing. Their showroom is conveniently located in Cashiers, NC.

Media Contact
Company Name: Granite Countertops Unlimited
Contact Person: Greg Moon
Email: Send Email
Phone: (828) 547-4993
Address:181 US-64 SUITE B
City: Cashiers
State: NC
Country: United States
Website: https://www.granitecountertopsunlimited.com/cashiers/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Experts at Granite Countertops Unlimited Discuss the Benefits of Granite for Homeowners in the Greater Cashiers NC Area

The Future of Basketball Coverage Has Arrived on Instagram Threads

The game has changed. The way we experience basketball has evolved. Old media is out—CourtSideHeatNBA is in.

Introducing CourtSideHeatNBA on Instagram Threads, the new, revolutionary hub for basketball fans of all kinds. Whether you’re a diehard, casual, new, or lifelong fan, CourtSideHeat is built for YOU.

No more outdated narratives. No more out-of-touch analysis. CourtSideHeat delivers real-time coverage, insider takes, and breaking news—all designed to make your fan experience better than ever.

From the latest trades and game recaps to bold opinions and exclusive insights, CourtSideHeat goes beyond the highlights to bring you the stories that matter. This isn’t just another basketball page but your new basketball home.

So, what are you waiting for?

Follow @CourtSideHeatNBAon Threads and experience basketball like never before!

About CourtSideHeat:

It’s the modern fan’s go-to source for breaking NBA news, in-depth analysis, game coverage, and insider perspectives. With a commitment to authentic, high-energy basketball content, CourtSideHeat is redefining how fans engage with the game.

Media Contact
Company Name: CourtSideHeat
Contact Person: Joshua Unangst
Email: Send Email
Country: United States
Website: https://courtsideheat.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Future of Basketball Coverage Has Arrived on Instagram Threads

Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approvals, Therapies, and Companies by DelveInsight

“Chemotherapy Induced Anemia Drugs Market”
Chemotherapy-Induced Anemia Companies include Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.

(Albany, USA) DelveInsight’s “Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chemotherapy Induced Anemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chemotherapy Induced Anemia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chemotherapy Induced Anemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chemotherapy Induced Anemia market.

 

Request for a Free Sample Report @ Chemotherapy Induced Anemia Market Forecast

 

Some facts of the Chemotherapy Induced Anemia Market Report are:

  • According to DelveInsight, Chemotherapy Induced Anemia market size is expected to grow at a decent CAGR by 2032.
  • The Chemotherapy Induced Anemia market size in the seven major markets was over USD 1 billion in 2021.
  • Leading Chemotherapy Induced Anemia companies working in the market are Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.
  • Key Chemotherapy Induced Anemia Therapies expected to launch in the market are Roxadustat (FG-4592), ALRN-6924, Desidustat, and many others.
  • In May 2024, Xyphos Biosciences, Inc., a wholly-owned subsidiary of Astellas, and Poseida Therapeutics, Inc., a publicly traded company, announced that they have formed a research collaboration and license agreement to create new convertible car programs. This will be achieved by combining the cutting-edge cell therapy platforms of both companies.
  • In March 2024, Elsevier, a world leader in providing information solutions and products for science, technology, and medicine, is pleased to announce the launch of a new open-access journal, CMI Communications, in collaboration with ESCMID, the leading European society for clinical microbiology and infectious diseases.
  • On June 2023, Fibrogen announced results of a Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

 

Chemotherapy Induced Anemia Overview

Chemotherapy-induced anemia (CIA) is a common complication of cancer treatment characterized by a decrease in red blood cell count and hemoglobin levels due to the cytotoxic effects of chemotherapy drugs on bone marrow function. Chemotherapy agents can suppress the production of red blood cells, leading to anemia, which can exacerbate symptoms and decrease quality of life in cancer patients.

The development of Chemotherapy-induced anemia depends on various factors, including the type and dose of chemotherapy drugs, the duration of treatment, the patient’s underlying health status, and the presence of other comorbidities. Symptoms of Chemotherapy-induced anemia may include fatigue, weakness, shortness of breath, dizziness, pale skin, and increased heart rate.

Managing Chemotherapy-induced anemia involves a multifaceted approach aimed at alleviating symptoms, improving hemoglobin levels, and maintaining quality of life for cancer patients. Treatment options may include red blood cell transfusions to quickly replenish hemoglobin levels, erythropoiesis-stimulating agents (ESAs) to stimulate red blood cell production, and iron supplementation to address underlying iron deficiency.

Additionally, supportive care measures such as optimizing nutritional status, managing comorbid conditions, and addressing any underlying causes of anemia are essential components of Chemotherapy-induced anemia management. Close monitoring of hemoglobin levels and symptoms, along with regular communication between healthcare providers and patients, is crucial to ensuring timely intervention and effective management of Chemotherapy-induced anemia during cancer treatment.

 

Do you know what will be the Chemotherapy Induced Anemia market share in 7MM by 2032 @ https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market

 

Chemotherapy Induced Anemia Market

The Chemotherapy Induced Anemia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Chemotherapy Induced Anemia market trends by analyzing the impact of current Chemotherapy Induced Anemia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Chemotherapy Induced Anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chemotherapy Induced Anemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chemotherapy Induced Anemia market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Chemotherapy Induced Anemia Epidemiology

The Chemotherapy Induced Anemia epidemiology section provides insights into the historical and current Chemotherapy Induced Anemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chemotherapy Induced Anemia market report also provides the diagnosed patient pool, trends, and assumptions.

 

Interested to know how the emerging diagnostic approaches will be contributing in increased Chemotherapy Induced Anemia diagnosed prevalence pool? Download report @ Chemotherapy Induced Anemia prevalence

 

Chemotherapy Induced Anemia Drugs Uptake

This section focuses on the uptake rate of the potential Chemotherapy Induced Anemia drugs recently launched in the Chemotherapy Induced Anemia market or expected to be launched in 2019-2032. The analysis covers the Chemotherapy Induced Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Chemotherapy Induced Anemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Chemotherapy Induced Anemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Chemotherapy Induced Anemia Pipeline Development Activities

The Chemotherapy Induced Anemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chemotherapy Induced Anemia key players involved in developing targeted therapeutics.

 

Download report to know which TOP 3 therapies will be capturing the largest Chemotherapy Induced Anemia market share by 2032? Click here @ https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-market

 

Chemotherapy Induced Anemia Therapeutics Assessment

Major key companies are working proactively in the Chemotherapy Induced Anemia Therapeutics market to develop novel therapies which will drive the Chemotherapy Induced Anemia treatment markets in the upcoming years are Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.

 

Download sample report @ Chemotherapy Induced Anemia Clinical Trials

 

Chemotherapy Induced Anemia Report Key Insights

1. Chemotherapy Induced Anemia Patient Population

2. Chemotherapy Induced Anemia Market Size and Trends

3. Key Cross Competition in the Chemotherapy Induced Anemia Market

4. Chemotherapy Induced Anemia Market Dynamics (Key Drivers and Barriers)

5. Chemotherapy Induced Anemia Market Opportunities

6. Chemotherapy Induced Anemia Therapeutic Approaches

7. Chemotherapy Induced Anemia Pipeline Analysis

8. Chemotherapy Induced Anemia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Chemotherapy Induced Anemia Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Chemotherapy Induced Anemia Competitive Intelligence Analysis

4. Chemotherapy Induced Anemia Market Overview at a Glance

5. Chemotherapy Induced Anemia Disease Background and Overview

6. Chemotherapy Induced Anemia Patient Journey

7. Chemotherapy Induced Anemia Epidemiology and Patient Population

8. Chemotherapy Induced Anemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Chemotherapy Induced Anemia Unmet Needs

10. Key Endpoints of Chemotherapy Induced Anemia Treatment

11. Chemotherapy Induced Anemia Marketed Products

12. Chemotherapy Induced Anemia Emerging Therapies

13. Chemotherapy Induced Anemia Seven Major Market Analysis

14. Attribute Analysis

15. Chemotherapy Induced Anemia Market Outlook (7 major markets)

16. Chemotherapy Induced Anemia Access and Reimbursement Overview

17. KOL Views on the Chemotherapy Induced Anemia Market

18. Chemotherapy Induced Anemia Market Drivers

19. Chemotherapy Induced Anemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/market-assessment-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approvals, Therapies, and Companies by DelveInsight

Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Metastatic Pancreatic Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Metastatic Pancreatic Cancer pipeline landscape. It covers the Metastatic Pancreatic Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Metastatic Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Pancreatic Cancer pipeline products in this space.

 

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Pancreatic Cancer Pipeline Report to explore emerging therapies, key Metastatic Pancreatic Cancer Companies, and future Metastatic Pancreatic Cancer treatment landscapes @ Metastatic Pancreatic Cancer Pipeline Outlook Report

 

Key Takeaways from the Metastatic Pancreatic Cancer Pipeline Report

  • In February 2025:- Erasca Inc.:- This is a Phase 1b/2, open-label, multicenter clinical study evaluating ERAS-007 in combination with other cancer therapies in study participants with GI malignancies. This study will serve as a platform study, allowing for evaluation of safety/tolerability and efficacy of ERAS-007 in combination with other cancer therapies. The study will initially commence with dose escalation of ERAS-007 administered in combination with encorafenib and cetuximab in study participants with metastatic colorectal cancer (CRC) harboring B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation; and dose escalation of ERAS-007 administered in combination with palbociclib in study participants with metastatic CRC harboring Kirsten rat sarcoma (KRAS) or neuroblastoma rat sarcoma (NRAS) mutations and metastatic pancreatic adenocarcinoma with (PDAC) KRAS mutation.
  • In January 2025:- Shanghai Yizhong Pharmaceutical Co., Ltd.-This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.
  • In January 2025: – Verastem Inc.:- This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
  • DelveInsight’s Metastatic Pancreatic Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Metastatic Pancreatic Cancer treatment.
  • The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
  • Promising Metastatic Pancreatic Cancer Therapies such as Parvovirus H-1 (H-1PV), Sunitinib, Napabucasin, Nab-paclitaxel, Gemcitabine, Dasatinib, mFOLFOX6, and others.

 

Discover how the Metastatic Pancreatic Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Pancreatic Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Pancreatic Cancer Clinical Trials and Studies

 

Metastatic Pancreatic Cancer Emerging Drugs Profile

  • Motixafortide: BioLineRx

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.

 

  • Fuzuloparib: Jiangsu Hengrui Pharmaceuticals

Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.

 

  • HP518: Hinova Pharmaceuticals

HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

 

The Metastatic Pancreatic Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Pancreatic Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Pancreatic Cancer Treatment.
  • Metastatic Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Pancreatic Cancer market.

 

Get a detailed analysis of the latest innovations in the Metastatic Pancreatic Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Pancreatic Cancer Unmet Needs

 

Metastatic Pancreatic Cancer Companies

Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.

 

Metastatic Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous

 

Metastatic Pancreatic Cancer Products have been categorized under various Molecule types such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Pancreatic Cancer Therapies and key Metastatic Pancreatic Cancer Developments @ Metastatic Pancreatic Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Metastatic Pancreatic Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Pancreatic Cancer Companies-Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
  • Promising Metastatic Pancreatic Cancer Therapies– Parvovirus H-1 (H-1PV), Sunitinib, Napabucasin, Nab-paclitaxel, Gemcitabine, Dasatinib, mFOLFOX6, and others.
  • Metastatic Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Which companies are leading the race in Metastatic Pancreatic Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Pancreatic Cancer Pipeline Report—access it now! @ Metastatic Pancreatic Cancer Emerging Drugs and Major Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Pancreatic Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Rucaparib: Eleison Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MDB 401 B: Panbela Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SBP 101: Takeda Oncology
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Pancreatic Cancer Key Companies
  21. Metastatic Pancreatic Cancer Key Products
  22. Metastatic Pancreatic Cancer- Unmet Needs
  23. Metastatic Pancreatic Cancer- Market Drivers and Barriers
  24. Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
  25. Metastatic Pancreatic Cancer Analyst Views
  26. Metastatic Pancreatic Cancer Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

How Coast Family Home Care’s Caregivers Are Addressing Social Isolation Among Seniors

Coast Family Home Care combats social isolation among seniors through personalized caregiving, fostering emotional support and social engagement to improve seniors’ well-being and quality of life.

Santa Maria, CA – Social isolation among seniors is a growing concern, with studies showing that nearly one in three older adults in the U.S. report feeling lonely or isolated. This issue has been exacerbated by the COVID-19 pandemic, which increased social distancing measures and limited in-person interactions, particularly for older adults. The consequences of isolation include an increased risk of depression, cognitive decline, and a decline in overall health. A report by the National Institute on Aging emphasizes that socially isolated seniors are at a higher risk for conditions such as heart disease, high blood pressure, and even premature death.

In response to these alarming trends, Coast Family Home Care has made it a priority to address social isolation among seniors through their compassionate, personalized caregiving services. The agency’s caregivers not only assist with daily activities but also foster meaningful connections with clients, providing emotional support, companionship, and engagement in social activities. This holistic approach is essential to improving the mental and emotional well-being of seniors.

Coast Family Home Care recognizes the critical need for senior companionship and ensures that caregivers are trained to build trustful relationships with clients. The company also encourages participation in activities like puzzles, games, walks, and virtual connections with family members, which help combat loneliness and provide an avenue for social interaction. These efforts are part of Coast Family Home Care’s broader mission to improve the quality of life for seniors in their own homes, ensuring they remain engaged with their communities and loved ones.

As the demand for home care services continues to grow, Coast Family Home Care is at the forefront of creating solutions that prioritize the social and emotional needs of seniors, ensuring they lead fulfilling and connected lives.

For more information, please visit Coast Family Home Care in Santa Maria.

About Coast Family Home Care:

Coast Family Home Care provides compassionate in-home care services, specializing in supporting seniors with daily activities, companionship, and specialized care plans. Their dedicated team of caregivers ensures that seniors receive high-quality care.

Media Contact
Company Name: Coast Family Home Care
Contact Person: Shirley Minyard
Email: Send Email
Phone: (805) 934-0600
Address:110 N. McClelland street
City: Santa Maria
State: California
Country: United States
Website: https://coastfamilyhomecare.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How Coast Family Home Care’s Caregivers Are Addressing Social Isolation Among Seniors